Metis Global Partners LLC Sells 1,310 Shares of BioMarin Pharmaceutical Inc. $BMRN

by · The Cerbat Gem

Metis Global Partners LLC trimmed its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 19.1% in the second quarter, Holdings Channel.com reports. The fund owned 5,560 shares of the biotechnology company’s stock after selling 1,310 shares during the quarter. Metis Global Partners LLC’s holdings in BioMarin Pharmaceutical were worth $306,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Nisa Investment Advisors LLC raised its position in BioMarin Pharmaceutical by 5.0% in the first quarter. Nisa Investment Advisors LLC now owns 4,572 shares of the biotechnology company’s stock worth $323,000 after purchasing an additional 217 shares in the last quarter. Cerity Partners LLC grew its stake in shares of BioMarin Pharmaceutical by 203.7% in the 1st quarter. Cerity Partners LLC now owns 84,832 shares of the biotechnology company’s stock valued at $5,997,000 after purchasing an additional 56,897 shares during the period. CWM LLC raised its holdings in shares of BioMarin Pharmaceutical by 128.2% in the 1st quarter. CWM LLC now owns 60,061 shares of the biotechnology company’s stock worth $4,246,000 after buying an additional 33,746 shares in the last quarter. Signaturefd LLC lifted its position in shares of BioMarin Pharmaceutical by 19.1% during the 1st quarter. Signaturefd LLC now owns 2,191 shares of the biotechnology company’s stock worth $155,000 after buying an additional 352 shares during the period. Finally, Wealthfront Advisers LLC acquired a new stake in BioMarin Pharmaceutical in the 1st quarter valued at $288,000. 98.71% of the stock is currently owned by institutional investors and hedge funds.

BioMarin Pharmaceutical Trading Down 2.0%

BMRN opened at $54.22 on Friday. BioMarin Pharmaceutical Inc. has a 1-year low of $50.76 and a 1-year high of $73.51. The stock has a market capitalization of $10.42 billion, a PE ratio of 20.38, a PEG ratio of 0.68 and a beta of 0.33. The company has a current ratio of 4.83, a quick ratio of 3.60 and a debt-to-equity ratio of 0.10. The firm has a 50-day moving average price of $53.87 and a two-hundred day moving average price of $56.63.

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) last posted its quarterly earnings data on Monday, October 27th. The biotechnology company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.20). BioMarin Pharmaceutical had a return on equity of 9.53% and a net margin of 16.82%.The company had revenue of $776.13 million during the quarter, compared to the consensus estimate of $782.42 million. During the same quarter last year, the firm earned $0.91 EPS. The business’s revenue for the quarter was up 4.1% on a year-over-year basis. BioMarin Pharmaceutical has set its FY 2025 guidance at 3.500-3.600 EPS. As a group, equities analysts anticipate that BioMarin Pharmaceutical Inc. will post 3.15 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on BMRN. Wedbush reiterated an “outperform” rating and issued a $94.00 price target on shares of BioMarin Pharmaceutical in a research report on Tuesday, October 28th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of BioMarin Pharmaceutical in a report on Wednesday, October 8th. UBS Group lifted their price target on shares of BioMarin Pharmaceutical from $113.00 to $114.00 and gave the company a “buy” rating in a report on Tuesday, August 5th. Morgan Stanley decreased their price objective on shares of BioMarin Pharmaceutical from $104.00 to $98.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 28th. Finally, Stifel Nicolaus reaffirmed a “hold” rating and set a $61.00 price objective (down previously from $73.00) on shares of BioMarin Pharmaceutical in a report on Thursday, November 6th. Sixteen research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $89.91.

View Our Latest Research Report on BioMarin Pharmaceutical

BioMarin Pharmaceutical Company Profile

(Free Report)

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Featured Stories

Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report).